Faron and Priaxon Announce a Collaboration to Generate a New Class of AOC3/SSAO Antagonist
Published: Jun 14, 2010
MUNICH & TURKU, Finland--(BUSINESS WIRE)--Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions. The goal of the collaboration is to create completely new scaffold structures to modify this interaction and the AOC3 function with orally available drugs.